Evidence- Based Practice Project- Paper on Diabetes
Grand Canyon University: NRS-410V

Evidence -Based practice project- Closed Loop Insulin Delivery System on Type 1 Diabetes

Type 1diabetes is a T-cell mediated autoimmune disease with increased morbidity and mortality leading to low quality life and its prevalence is sky-rocketing. Different methods and technology have been implemented to control the diabetes. This paper will describe about the research project which is about treatment of patients with type 1 diabetes with close loop insulin delivery system. A closed-loop insulin delivery system (also known as artificial pancreas) is one of the best therapeutic approaches by the researchers for the control of blood glucose level in type 1 diabetes till now. “The artificial pancreas is a system of integrated devices containing only synthetic materials, which substitutes for a pancreas by sensing plasma glucose concentration, calculating the amount of insulin needed, and then delivering the correct amount of insulin” (Sasi & Elmalki, 2013).
Research and Clinical Findings:

Among the various research articles on diabetes, “Home Use of an Artificial Beta Cell in Type 1 Diabetes” by Thabit et al is a very resourceful paper that was published in The New England Journal of Medicine in 2015. This research paper tests the practicability, efficiency and safety of artificial pancreas in the home settings. It is crossover, randomized controlled studies which included the 58 people of two age group [(6-18 years) – 25 participants & above 18 years- 33 participants] with type 1 diabetes and the duration of the study is 12 weeks. During the tenure of this study, closed-loop insulin delivery system was compared with the sensor-augmented pump therapy; adult group used the closed-loop day and night while the children group used overnight only for 12 weeks while the sensor augmented pump therapy for control group for a similar period. However, continuous glucose-monitoring device (CGMD) has been wore by both study and control group. By the use of CGMD, glucose level ranging 70 to 180 mg per deciliter is considered as the primary end point for adult group and 70 to 145 mg per deciliter for children group (Thabit et al., 2015).